Syndax Pharmaceuticals
SNDX
68 hedge funds and large institutions have $176M invested in Syndax Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 33 increasing their positions, 14 reducing their positions, and 7 closing their positions.
136% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 14
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
3% more funds holding
Funds holding: 66 → 68 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3.72% less ownership
Funds ownership: 71.39% → 67.67% (-3.7%)
20% less capital invested
Capital invested by funds: $219M → $176M (-$43.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$1.5M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.12M |
| 3 |
BlackRock
New York
|
+$770K |
| 4 |
CCI
Columbus Circle Investors
|
+$521K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$509K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$4.01M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.99M |
| 3 |
GTC
Ghost Tree Capital
New York
|
-$2.79M |
| 4 |
AG
Artal Group
Luxembourg
|
-$1.8M |
| 5 |
BC
Boxer Capital
San Diego,
California
|
-$1.65M |
SNDX Hedge Fund Activity: Q3 2017 in Review
68 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q3 2017, worth a combined $176M — down 20% from $219M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new SNDX positions and 7 closed out — a net gain of 3 holders — while 33 added to existing stakes and 14 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $1.5M. The largest seller was Millennium Management, cutting an estimated $4.01M.
- 68 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q3 2017, up from 66 in Q2 2017.
- Funds reported $176M of Syndax Pharmaceuticals stock for Q3 2017, down 20% quarter-over-quarter.
- 10 funds opened new Syndax Pharmaceuticals positions in Q3 2017 and 7 closed out, a net change of +3 holders.
- The largest Syndax Pharmaceuticals buyer in Q3 2017 was Morgan Stanley, an estimated $1.5M added.
- The largest Syndax Pharmaceuticals seller in Q3 2017 was Millennium Management, an estimated $4.01M sold.
Based on aggregated 13F filings for Q3 2017.